Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1973 May;52(5):1010–1017. doi: 10.1172/JCI107265

Effects of Replacement Doses of Sodium-L-Thyroxine on the Peripheral Metabolism of Thyroxine and Triiodothyronine in Man

Lewis E Braverman 1,2,3,4,5,6,7, Apostolos Vagenakis 1,2,3,4,5,6,7, Patricia Downs 1,2,3,4,5,6,7, Angela E Foster 1,2,3,4,5,6,7, Kenneth Sterling 1,2,3,4,5,6,7, Sidney H Ingbar 1,2,3,4,5,6,7
PMCID: PMC302354  PMID: 4700481

Abstract

Studies of the effect of L-thyroxine administration (0.3 mg daily for 7-9 wk) on the peripheral metabolism of 131I-labeled triiodothyronine (T3) and 125I-labeled thyroxine (T4) and on the concentration and binding of T4 and T3 in serum were carried out in 11 euthyroid female subjects. Administration of L-thyroxine led to consistent increases in serum T3 concentration (137 vs. 197 ng/100 ml), T3 distribution space (39.3 vs. 51.7 liters), T3 clearance rate (22.9 vs. 30.6 liters/day) and absolute T3 disposal rate (30 vs. 58 μg/day), but no change in apparent fractional turnover rate (60.3 vs. 60.6%/day). The proportion and absolute concentration of free T3 also increased during L-thyroxine administration. Increases in serum total T4 concentration (7.3 vs. 12.8 μg/100 ml) and in both the proportion and absolute concentration of free thyroxine also occurred. In five of the subjects, the kinetics of peripheral T4 turnover were simultaneously determined and a consistent increase in fractional turnover rate (9.7 vs. 14.2%/day), clearance rate (0.84 vs. 1.37 liters/day), and absolute disposal rate (64.2 vs. 185.0 μg/day) occurred during L-thyroxine administration. Despite these increases in the serum concentration and daily disposal rate of both T4 and T3, the patients were not clinically thyrotoxic. However, basal metabolic rate (BMR) values were marginally elevated and, as in frank thyrotoxicosis, T4-binding capacities of thyroxine-binding globulin (TBG) and thyroxine-binding prealbumin (TBPA) reduced, suggesting that subclinical thyrotoxicosis was present. Thus, the often recommended replacement dose of 0.3 mg L-thyroxine daily may be greater than that required to achieve the euthyroid state.

The studies have also provided additional evidence of the peripheral conversion of T4 to T3 in man and have permitted the calculation that approximately one-third of exogenously administered T4 underwent deiodination to form T3. To the extent that a similar fractional conversion occurs in the normal state, it can be calculated that a major fraction of the T3 in serum derives from the peripheral deiodination of T4 and that only a lesser fraction derives from direct secretion by the thyroid gland.

Full text

PDF
1010

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ALBRIGHT E. C., LARSON F. C. Metabolism of L-thyroxine by human tissue slices. J Clin Invest. 1959 Nov;38:1899–1903. doi: 10.1172/JCI103967. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. BERSON S. A., YALOW R. S. Quantitative aspects of iodine metabolism: the exchangeable organic iodine pool, and the rates of thyroidal secretion, peripheral degradation and fecal excretion, of endogenously synthesized organically bound iodine. J Clin Invest. 1954 Nov;33(11):1533–1552. doi: 10.1172/JCI103032. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Braverman L. E., AvRuskin T., Cullen M. J., Vagenakis A. G., Ingbar S. H. Effects of norethandrolone on the transport and peripheral metabolism of thyroxine in patients lacking thyroxine-binding globulin. Observations on the physiological role of thyroxine-binding prealbumin. J Clin Invest. 1971 Aug;50(8):1644–1649. doi: 10.1172/JCI106653. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Braverman L. E., Foster A. E., Ingbar S. H. Thyroid hormone transport in the serum of patients with thyrotoxic Graves' disease before and after treatment. J Clin Invest. 1968 Jun;47(6):1349–1357. doi: 10.1172/JCI105827. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Braverman L. E., Ingbar S. H., Sterling K. Conversion of thyroxine (T4) to triiodothyronine (T3) in athyreotic human subjects. J Clin Invest. 1970 May;49(5):855–864. doi: 10.1172/JCI106304. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Braverman L. E., Vagenakis A. G., Foster A. E., Ingbar S. H. Evaluation of a simplified technique for the specific measurement of serum thyroxine concentration. J Clin Endocrinol Metab. 1971 Apr;32(4):497–502. doi: 10.1210/jcem-32-4-497. [DOI] [PubMed] [Google Scholar]
  7. Cavalieri R. R., Steinberg M., Searle G. L. Metabolic clearance rate of L-triiodothyronine in man: a comparison of results by single-injection and constant infusion methods. J Clin Endocrinol Metab. 1971 Oct;33(4):624–629. doi: 10.1210/jcem-33-4-624. [DOI] [PubMed] [Google Scholar]
  8. Cotton G. E., Gorman C. A., Mayberry W. E. Suppression of thyrotropin (h-TSH) in serums of patients with myxedema of varying etiology treated with thyroid hormones. N Engl J Med. 1971 Sep 2;285(10):529–533. doi: 10.1056/NEJM197109022851001. [DOI] [PubMed] [Google Scholar]
  9. Farmer T. A., Jr, Smitherman T. C., Beschi R. J., Pittman J. A., Jr Effect of triiodothyronine administration on serum PBI in hypothyroid patients maintained on constant doses of thyroxine. J Clin Endocrinol Metab. 1969 Jun;29(6):781–785. doi: 10.1210/jcem-29-6-781. [DOI] [PubMed] [Google Scholar]
  10. Gharib H., Mayberry W. E., Ryan R. J. Radioimmunoassay for triiodothyronine: A preliminary report. J Clin Endocrinol Metab. 1970 Dec;31(6):709–712. doi: 10.1210/jcem-31-6-709. [DOI] [PubMed] [Google Scholar]
  11. Hart F. D., Maclagan N. F. Oral Thyroxine in the Treatment of Myxoedema. Br Med J. 1950 Mar 4;1(4652):512–518. doi: 10.1136/bmj.1.4652.512. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. INADA M., KOSHIYAMA K., TORIZUKA K., AKAGI H., MIYAKE T. CLINICAL STUDIES ON THE METABOLISM OF 131-I-LABELED L-THYROXINE. J Clin Endocrinol Metab. 1964 Aug;24:775–784. doi: 10.1210/jcem-24-8-775. [DOI] [PubMed] [Google Scholar]
  13. INGBAR S. H., FREINKEL N. Simultaneous estimation of rates of thyroxine degradation and thyroid hormone synthesis. J Clin Invest. 1955 Jun;34(6):808–819. doi: 10.1172/JCI103136. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Inada M., Sterling K. Thyroxine transport in thyrotoxicosis and hypothyroidism. J Clin Invest. 1967 Sep;46(9):1442–1450. doi: 10.1172/JCI105636. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Ingbar S. H., Braverman L. E., Dawber N. A., Lee G. Y. A new method for measuring the free thyroid hormone in human serum and an analysis of the factors that influence its concentration. J Clin Invest. 1965 Oct;44(10):1679–1689. doi: 10.1172/JCI105275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. LAVIETES P. H., EPSTEIN F. H. THYROID THERAPY OF MYXEDEMA: A COMPARISON OF VARIOUS AGENTS WITH A NOTE ON THE COMPOSITION OF THYROID SECRETION IN MAN. Ann Intern Med. 1964 Jan;60:79–87. doi: 10.7326/0003-4819-60-1-79. [DOI] [PubMed] [Google Scholar]
  17. Lieblich J., Utiger R. D. Triiodothyronine radioimmunoassay. J Clin Invest. 1972 Jan;51(1):157–166. doi: 10.1172/JCI106786. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. MACGREGOR A. G. Why does anybody use thyroid B.P.? Lancet. 1961 Feb 11;1(7172):329–332. doi: 10.1016/s0140-6736(61)91498-2. [DOI] [PubMed] [Google Scholar]
  19. MCGAVACK T. H., RECKENDORF H. K. Therapeutic activity of desiccated thyroid substance, sodium L-thyroxine and D, L-triiodothyronine; a comparative study. Am J Med. 1956 May;20(5):774–777. doi: 10.1016/0002-9343(56)90159-0. [DOI] [PubMed] [Google Scholar]
  20. Nicoloff J. T., Dowling J. T. Studies of peripheral thyroxine distribution in thyrotoxicosis and hypothyroidism. J Clin Invest. 1968 Sep;47(9):2000–2015. doi: 10.1172/JCI105887. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Nicoloff J. T., Low J. C., Dussault J. H., Fisher D. A. Simultaneous measurement of thyroxine and triiodothyronine peripheral turnover kinetics in man. J Clin Invest. 1972 Mar;51(3):473–483. doi: 10.1172/JCI106835. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Oddie T. H., Fisher D. A., Dussault J. H., Thompson C. S. Triiodothyronine turnover in euthyroid subjects. J Clin Endocrinol Metab. 1971 Oct;33(4):653–660. doi: 10.1210/jcem-33-4-653. [DOI] [PubMed] [Google Scholar]
  23. Pittman C. S., Chambers J. B., Jr, Read V. H. The extrathyroidal conversion rate of thyroxine to triiodothyronine in normal man. J Clin Invest. 1971 Jun;50(6):1187–1196. doi: 10.1172/JCI106596. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. ROBERTSON J. D., KIRKPATRICK H. F. W. Changes in basal metabolism, serumprotein-bound iodine, and cholesterol during treatment of hypothyroidism with oral thyroid and L-thyroxine sodium. Br Med J. 1952 Mar 22;1(4759):624–628. doi: 10.1136/bmj.1.4759.624. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. SALTER W. T., ROSENBLUM I. Oral sodium L-thyroxine in the treatment of myxedema and cretinism. Am J Med Sci. 1952 Dec;224(6):628–631. doi: 10.1097/00000441-195212000-00005. [DOI] [PubMed] [Google Scholar]
  26. SELENKOW H. A., ASPER S. P., Jr The effectiveness of triiodothyronine or thyroxine administered orally in the treatment of myxedema. J Clin Endocrinol Metab. 1955 Mar;15(3):285–296. doi: 10.1210/jcem-15-3-285. [DOI] [PubMed] [Google Scholar]
  27. STERLING K., CHODOS R. B. Radiothyroxine turnover studies in myxedema, thyrotoxicosis, and hypermetabolism without endocrine disease. J Clin Invest. 1956 Jul;35(7):806–813. doi: 10.1172/JCI103333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. STERLING K. Radiothyroxine turnover studies in thyroid disease after therapy. J Clin Invest. 1958 Oct;37(10):1348–1356. doi: 10.1172/JCI103724. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Schwartz H. L., Surks M. I., Oppenheimer J. H. Quantitation of extrathyroidal conversion of L-thyroxine to 3,5,3'-triiodo-L-thyronine in the rat. J Clin Invest. 1971 May;50(5):1124–1130. doi: 10.1172/JCI106584. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Solomon D. H., Benotti J., DeGroot L. J., Greer M. A., Pileggi V. J., Pittman J. A., Robbins J., Selenkow H. A., Sterling K., Volpe R. A nomenclature for tests of thyroid hormones in serum: report of a committee of the American Thyroid Association. J Clin Endocrinol Metab. 1972 May;34(5):884–890. doi: 10.1210/jcem-34-5-884. [DOI] [PubMed] [Google Scholar]
  31. Sterling K., Bellabarba D., Newman E. S., Brenner M. A. Determination of triiodothyronine concentration in human serum. J Clin Invest. 1969 Jun;48(6):1150–1158. doi: 10.1172/JCI106072. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Surks M. I., Oppenheimer J. H. Formation of iodoprotein during the peripheral metabolism of 3,5,3'-triiodo-L-thyronine-125I in the euthyroid man and rat. J Clin Invest. 1969 Apr;48(4):685–695. doi: 10.1172/JCI106026. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Woeber K. A., Sobel R. J., Ingbar S. H., Sterling K. The peripheral metabolism of triiodothyronine in normal subjects and in patients with hyperthyroidism. J Clin Invest. 1970 Apr;49(4):643–649. doi: 10.1172/JCI106275. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES